2-Acetyl-1,3-Cyclopentanedione for the Treatment of Metabolic Disorders
Prevents development of the diseaseDiminishes the pre-existing presence of the disease
Treatment of obesity. diabetes mellitus, metabolic syndrome, healthcare, pharmaceutical industires
Our inventors have successfully discovered 2-acetyl-1,3-cyclopentanedione (ACDP); ACPD has the potential to completely prevent development of, or reverse or diminish the pre-existing presence of, the diseases aforementioned. The technology is a novel, highly specific, potent, small molecular weight inhibitor of both atypical PKCs, PKC-zeta and PKC-lambda/iota. Effective treatment by a single agent for these abnormalities is promising for treating what is considered the major health concern of modern day; the obesity, metabolic syndrome, type 2 diabetes pandemic that constitute much of the cardiovascular disease.
美國
